Dr. Melisko is a nationally recognized expert in the management of patients with breast cancer. She focuses on investigating new treatments for early and late stage disease, and particularly in patients with central nervous system metastases. She has been the principal investigator for multiple clinical trials for patients with brain metastases and leptomeningeal disease and has published on novel agents to treat these conditions and on methods to quantify and molecularly characterize tumor cells isolated from the cerebrospinal fluid. She is an active member of the UCSF Developmental Therapeutics/Phase 1 Program. She also conducts research on symptom management, patient reported outcomes, and survivorship issues in breast cancer patients. She is the Medical Director of the UCSF Breast Care Center (BCC) Survivorship Program, the co-chair of the Translation Breast Cancer Research Consortium (TBCRC) Patient Reported Outcomes (PRO) Interest Group, and a founding member of the PRO working group within the ISPY2 clinical trial investigating novel agents in the neoadjuvant setting. She is also a member of the NCCN Survivorship panel and has published multiple papers on symptom reporting and management.